期刊文献+
共找到13,163篇文章
< 1 2 250 >
每页显示 20 50 100
The Clinical Usefulness of ^(99m)Tc-Tetrofosmin Scintigraphy in the Diagnosis of Lung Neoplasmas and Mediastinal Lymphoid Node Involvement 被引量:6
1
作者 黄代娟 赵峰 张永学 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2008年第5期608-612,共5页
In order to investigate the clinical significance of 99mTc-Tetrofosmin (TF) scintigraphy in the evaluation of lung cancer and mediastinal lymphoid node involvement, 33 patients with pulmo- nary neoplasmas were subje... In order to investigate the clinical significance of 99mTc-Tetrofosmin (TF) scintigraphy in the evaluation of lung cancer and mediastinal lymphoid node involvement, 33 patients with pulmo- nary neoplasmas were subjected to both 99mTc-TF scintigraphies and CT scans in one week before their operations or puncturations. All the images were judged visually and the emission images were analyzed with semi-quantitative methods in addition. The results of each group were compared. There was marked difference in target/non-target (T/N) ratio between the lung cancer group and the benign lesion group (P〈0.001). Moreover, in the lung cancer group, T/N ratio in tomographies was signifi- cantly higher than that in planar images (P〈0.01). The sensitivity and accuracy of semi-quantitative analysis in 99mTc-TF SPECT were significantly higher than those of CT in the diagnosis of pulmonary neoplasmas (P〈0.05 and P〈0.01 respectively), so was the sensitivity of 99mTc-TF SPECT vs CT in the diagnosis of mediastinal lymphoid node metastasis (P〈0.05). It was also found that epidermoid squamous cell carcinomas and adenocarcinomas had a higher T/N ratio than in small cell carcinomas (P〈0.05), and 2 h washout rate (WR) of adenocarcinomas was higher than that of epidermoid squamous cell carcinomas (P〈0.05). In conclusion, 99mTc-TF scintigraphy showed a favorable diag- nostic accuracy in appraising lung cancers and mediastinal lymph node metastases. Furthermore semi-quantitative technology can improve the accuracy, and is potential to offer some information about histological type of the cancer tissue. Therefore, 99mTc-TF scintigraphy will be a useful tool in the diagnosis and staging of lung cancer. 展开更多
关键词 lung neoplasm MEDIASTINUM lymph node 99MTC-TETROFOSMIN scINTIGRAPHY
下载PDF
COX-2/PGE2/EP4轴诱导巨噬细胞功能活化在NSCLC发展过程中的作用
2
作者 赵娟 朱倩莹 +4 位作者 张宇 黎贵芸 张映林 李方方 边莉 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第4期245-256,共12页
背景与目的肿瘤微环境(tumor microenvironment,TME)是肿瘤发生、发展的重要因素之一,其中肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)在非小细胞肺癌(non-small cell lung cancer,NSCLC)进展中起着重要作用。然而,TAMs在NSCL... 背景与目的肿瘤微环境(tumor microenvironment,TME)是肿瘤发生、发展的重要因素之一,其中肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)在非小细胞肺癌(non-small cell lung cancer,NSCLC)进展中起着重要作用。然而,TAMs在NSCLC发展过程中的作用机制仍不清楚,因此本研究旨在探讨TAMs在NSCLC发展过程中的作用,并寻找潜在的治疗靶点。方法使用GEPIA(Gene Expression Profiling Interactive Analysis)数据库分析前列腺素E2受体4(prostaglandin E2 receptor 4,EP4)mRNA在NSCLC和正常肺组织中的表达情况;利用免疫组化(immunohistochemistry,IHC)方法检测120例NSCLC组织及24例癌旁组织标本中环氧合酶-2(cyclooxygenase-2,COX-2)、EP4、分化簇86(cluster of differentiation 86,CD86)、CD163、CD31的蛋白表达水平;建立裸鼠肺腺癌细胞A549与巨噬细胞RAW264.7共移植瘤模型,使用EP4抑制剂E7046灌胃,收集样本行苏木素-伊红(hematoxylin-eosin,HE)、IHC和免疫荧光(immunofluorescence,IF)染色,免疫印迹(Western blot)检测各组裸鼠肿瘤组织上皮间充质转化(epithelial-mesenchymal transformation,EMT)相关蛋白表达情况;全长转录组测序技术筛选引起肿瘤肝转移的关键基因并进行KEGG(Kyoto Encyclopedia of Genes and Genomes)富集分析。结果EP4 mRNA在NSCLC组织中表达水平普遍低于正常肺组织(P<0.05);COX-2、EP4、CD163、CD31蛋白在NSCLC组织和癌旁组织中差异性表达且在NSCLC患者多项临床病理参数中存在差异;RAW264.7缩短了A549的成瘤潜伏期,促进肿瘤增殖及肿瘤肝转移,E7046可降低裸鼠肿瘤细胞增殖活性、肿瘤组织血管密度及M2型巨噬细胞浸润;IF染色显示巨噬细胞主要分布在肿瘤转移灶周围;Western blot结果显示与A549单独移植组相比,A549与RAW264.7共移植组小鼠肿瘤组织中E-钙黏蛋白(E-cadherin)相对表达量明显降低,差异具有统计学意义(P<0.05),N-钙黏蛋白(N-cadherin)相对表达量上调,但差异无统计学意义(P>0.05);全长转录组差异基因主要富集的通路为PI3K-AKT、MAPK信号通路。结论在NSCLC发生发展过程中,COX-2/PGE2/EP4轴可能通过诱导巨噬细胞功能活化来促进肿瘤的进展,EP4可能是具有潜力的肿瘤免疫治疗新靶点。本研究为深入探讨NSCLC的发生发展机制提供了新的视角和思路,同时为开发新的NSCLC治疗策略提供了理论依据。 展开更多
关键词 肺肿瘤 PGE2 EP4 巨噬细胞 肿瘤免疫
下载PDF
EGFR突变可切除的NSCLC围手术期辅助靶向治疗研究进展及问题探讨
3
作者 宋朋 崔永 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第5期383-390,共8页
肺癌在全球范围内仍是导致癌症死亡的首要原因,非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌的主要病理类型,占80%左右。在所有NSCLC患者中,约30%初诊时为可切除的早中期NSCLC。近期表皮生长因子受体-酪氨酸激酶抑制剂(epider... 肺癌在全球范围内仍是导致癌症死亡的首要原因,非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌的主要病理类型,占80%左右。在所有NSCLC患者中,约30%初诊时为可切除的早中期NSCLC。近期表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)在EGFR突变可切除的NSCLC围手术期辅助靶向治疗中取得重大突破,并被指南推荐应用于临床。本文在总结EGFR突变可切除NSCLC围手术期辅助靶向治疗临床研究进展的基础上,针对临床研究中的关键问题进行探讨。 展开更多
关键词 肺肿瘤 围手术期治疗 新辅助治疗 辅助治疗 靶向治疗
下载PDF
SIGNIFICANCE OF ELECTRON MICROSCOPIC EXAMINATION IN THE DIAGNOSIS OF PULMONARY NEOPLASMS
4
作者 童茂荣 周晓军 +2 位作者 康晓明 夏锡荣 施毅 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1995年第1期61-65,共5页
The significance of electronic microscopc examination(EM) in the diagnosis of pulmonary neoplasms was evaIuated in 40 cases of Patients with different kinds of Pulmonary neoplasms.In 27 of the 40 cases,final diagnoses... The significance of electronic microscopc examination(EM) in the diagnosis of pulmonary neoplasms was evaIuated in 40 cases of Patients with different kinds of Pulmonary neoplasms.In 27 of the 40 cases,final diagnoses were made by light microscope(LM) examination,while in the remaining 13 cases,LM faded to reach definite diagnoses which were established with the help of EM.By analyzing our data,we conclude that in the following situations,EM helps meet in the diagnosis of pulmonary neoplasm:1.diagnosis of neuroendocrinal carcinomas of the lung;2.diagnosis of some rare pulmonary neoplasm;3.documentation of the histologic origins of the matastatic pulmonary neoplasms and 4.differentiation of malignant mesothelioma with pleural metastasis of Pulmonary adenocarcinoma. 展开更多
关键词 Electronic microscope neoplasm lung.
下载PDF
老年晚期NSCLC患者PD-1/PD-L1免疫检查点抑制剂治疗现状及展望
5
作者 卯云烨 盛舒 +4 位作者 王安 翟今朝 葛祥伟 卢迪 汪进良 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第5期367-375,共9页
癌症发病率与年龄密切相关,75%的非小细胞肺癌(non-small cell lung cancer, NSCLC)患者年龄均≥65岁。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现改变了NSCLC的治疗格局。针对老年患者有限的研究发现对于65-75岁的患... 癌症发病率与年龄密切相关,75%的非小细胞肺癌(non-small cell lung cancer, NSCLC)患者年龄均≥65岁。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现改变了NSCLC的治疗格局。针对老年患者有限的研究发现对于65-75岁的患者,ICIs单药显示出良好的获益,与年轻患者无明显差异,这种获益在免疫联合化疗或放疗中也有所体现。但是对于≥75岁的患者来说生存获益不明显。ICIs单药在不同年龄段的患者中免疫相关不良反应(immune-related adverse events, irAEs)发生率相似,免疫联合化疗对比单纯化疗导致irAEs的发生率高,≥75岁患者发生更高级别irAEs的可能性更大。除了老年患者免疫衰老会从多维度影响免疫微环境从而影响免疫治疗疗效外,东部肿瘤协作组体力状态(Eastern Cooperative Oncology Group performance status, ECOG PS)评分等也会影响预后。对于部分≥75岁或身体状况较差的患者,免疫联合低强度化疗成为有潜力的治疗方式之一,但相关研究较少,所以应有意识增加老年患者入组试验的人数,同时综合评估,探索个体化治疗方案。本综述拟对老年NSCLC患者应用抗程序性死亡受体1(programmed cell death protein 1, PD-1)及其配体(programmed cell death ligand 1, PD-L1)的相关研究进行汇总分析,以期为老年NSCLC患者的免疫治疗提供更多参考和指导,并结合其特点提出新的治疗展望。 展开更多
关键词 肺肿瘤 老年非小细胞肺癌 免疫衰老 免疫治疗 免疫联合低强度化疗
下载PDF
MSCT诊断原发性肺腺泡细胞癌临床案例分析
6
作者 王琼 彭迪 +2 位作者 程少磊 黄治华 胡兴荣 《CT理论与应用研究(中英文)》 2024年第2期228-234,共7页
腺泡细胞癌(ACC)是一种涎腺上皮源性恶性肿瘤,主要发生于涎腺,而肺内原发腺泡细胞癌极其罕见。由于临床发病率非常低,相关文献报道少,临床医生对其认识不足,容易误诊而延误患者治疗。本文报道1例经手术病理证实的原发性肺腺泡细胞癌,并... 腺泡细胞癌(ACC)是一种涎腺上皮源性恶性肿瘤,主要发生于涎腺,而肺内原发腺泡细胞癌极其罕见。由于临床发病率非常低,相关文献报道少,临床医生对其认识不足,容易误诊而延误患者治疗。本文报道1例经手术病理证实的原发性肺腺泡细胞癌,并结合相关文献,总结本病的MSCT影像表现以及MSCT在本病诊疗中的价值,以提高对该病的认识和影像诊断水平。 展开更多
关键词 体层摄影术 X线计算机 诊断 肺肿瘤 腺泡细胞癌
下载PDF
^(99)Tc^(m)-DTPA-CGRRAGGSC在非小细胞肺癌裸鼠模型的显像研究
7
作者 李卫鹏 李辉 +3 位作者 刘春艳 沈如月 訾刚 袁超 《蚌埠医学院学报》 CAS 2024年第6期701-705,共5页
目的:探讨放射性核素^(99)Tc^(m)标记环九肽(CGRRAGGSC)对荷非小细胞肺癌裸鼠的显像研究。方法:用^(99)Tc^(m)标记DTPA-CGRRAGGSC,测定其标记率及稳定性,制备荷非小细胞肺癌小鼠模型,经荷瘤鼠尾静脉注射标记物2 h后进行SPECT静态显像,... 目的:探讨放射性核素^(99)Tc^(m)标记环九肽(CGRRAGGSC)对荷非小细胞肺癌裸鼠的显像研究。方法:用^(99)Tc^(m)标记DTPA-CGRRAGGSC,测定其标记率及稳定性,制备荷非小细胞肺癌小鼠模型,经荷瘤鼠尾静脉注射标记物2 h后进行SPECT静态显像,并计算出靶与非靶(T/NT)比值。结果:成功制备出^(99)Tc^(m)-DTPA-CGRRAGGSC,在PBS和人血清中37℃放置6 h时放射性化学纯度在90%以上;经荷瘤鼠尾静脉注射标记物2 h后T/NT比值最高达3.5。结论:^(99)Tc^(m)标记DTPA-CGRRAGGSC制备简便,其对荷非小细胞肺癌裸鼠具有较高靶向性,^(99)Tc^(m)-DTPA-CGRRAGGSC有可能在IL-11Rα高表达的非小细胞肺癌分子显像中发挥重要作用。 展开更多
关键词 肺肿瘤 ^(99)Tc^(m)标记环九肽 白细胞介素-11Rα 放射性核素标记
下载PDF
肺癌脑转移瘤DSC-PWI:ASL最佳标记延迟时间分析 被引量:2
8
作者 王旭 魏强 +3 位作者 刘义军 李贝贝 童小雨 范勇 《放射学实践》 CSCD 北大核心 2023年第4期394-400,共7页
目的:通过与动态磁敏感对比增强灌注成像(DSC-PWI)进行对比,探讨动脉自旋标记灌注成像(ASL-PWI)在评估肺癌脑转移时的最佳标记后延迟时间(PLD)。方法:前瞻性将在本院确诊为肺癌脑转移的33例患者纳入本研究。其中,肺腺癌18例,肺鳞癌15例... 目的:通过与动态磁敏感对比增强灌注成像(DSC-PWI)进行对比,探讨动脉自旋标记灌注成像(ASL-PWI)在评估肺癌脑转移时的最佳标记后延迟时间(PLD)。方法:前瞻性将在本院确诊为肺癌脑转移的33例患者纳入本研究。其中,肺腺癌18例,肺鳞癌15例。所有患者行DSC-PWI和不同PLD(1.0、1.5、2.0和2.5 s)3D-ASL-PWI扫描。由两位医师对4组(不同PLD)ASL-PWI伪彩图进行图像质量评分,并采用Kappa检验进行一致性评估。基于DSC-PWI的诊断结果,比较不同PLD的ASL-PWI对脑转移瘤的检出效能。测量ASL-PWI和DSC-PWI图像上肿瘤内异常灌注区和对侧镜像区的灌注参数值,并对脑血流量(CBF)和脑血容量(CBV)进行标准化,获得不同PLD ASL-PWI的rCBF及DSC-PWI的rCBF、rCBV、平均通过时间(MTT)和达峰时间(TTP)。不同PLD ASL-PWI的图像质量主观评分、肿瘤显示情况评级和rCBF值的比较采用Friedman秩和检验。ASL-rCBF与DSC-rCBF的比较采用Wilcoxon检验。采用Spearman检验分析ASL-PWI参数(rCBF)与DSC-PWI参数(rCBF、rCBV、MTT、TTP)的相关性。结果:不同PLD的ASL-PWI图像质量主观评分的差异有统计学意义(P<0.05),1.5 s PLD时图像质量主观评分最高,中位数为4.0(4.0,4.0)分。在1.5 s PLD时,ASL-PWI对肺腺癌和肺鳞癌脑转移瘤的显示能力评级最高,中位数均为2.0(1.0,2.0)级;检出率分别为100%和93.33%。随着PLD的增加,两种病理类型脑转移瘤的rCBF均逐渐增加(P<0.05);在PLD为1.5和2.0 s时,两者的ASL-rCBF与DSC-rCBF之间的差异均无统计学意义(P>0.05)。不同PLD时肺腺癌脑转移瘤的ASL-rCBF与DSC-rCBF和DSC-rCBV均具有相关性(P<0.05),以PLD为1.5 s时的相关性最高(r=0.910、0.794)。肺鳞癌脑转移瘤的ASL-rCBF在不同PLD时与DSC-rCBF均具有相关性(P<0.05),以PLD为1.5 s时的相关性最大(r=0.925),其与rCBV、MTT及TTP均无显著相关性(P>0.05)。结论:PLD为1.5 s时,ASL-PWI对肺癌(腺癌和鳞癌)脑转移的诊断效能最高,获得的rCBF值与DSC-PWI结果相近。 展开更多
关键词 脑转移瘤 肺肿瘤 动脉自旋标记 标记后延迟时间 动态磁敏感对比增强 灌注加权成像
下载PDF
Serum Vascular Endothelial Growth Factor Levels in Patients with Non-small Cell Lung Cancer and Its Relations to the Micrometastasis in Peripheral Blood 被引量:8
9
作者 金阳 熊先智 +2 位作者 苏远 胡建武 陶晓南 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2009年第4期462-465,共4页
To examine the relationship between the levels of the serum vascular endothelial growth factor (VEGF) and the micrometastasis of peripheral blood in patients with non-small cell lung cancer (NSCLC), 108 NSCLC pati... To examine the relationship between the levels of the serum vascular endothelial growth factor (VEGF) and the micrometastasis of peripheral blood in patients with non-small cell lung cancer (NSCLC), 108 NSCLC patients, including 40 patients with benign lung diseases and 30 healthy controls, were investigated. The serum VEGF levels were detected by ELISA and CK19 mRNA in peripheral blood by reverse transcriptase-polymerase chain reaction (RT-PCR). In NSCLC group, the serum VEGF levels and the positive rate of CK19 mRNA in peripheral blood were 479.8±268.5 pg/mL and 66.7%, which were significantly higher than those of the other two groups respectively (P〈0.01), and both of them were increased significantly with the progression of clinical stage of the tumors (P〈0.01). Serum VEGF levels as well as the positive rate of CK19 mRNA in different pathological types of lung cancer had no significant differences (P〉0.05). Serum VEGF levels in the patients positive for CK19 mRNA was 561.7±325.6 pg/mL. It is significantly higher than that in the negative patients (P〈0.01). There existed a significant correlation between serum VEGF levels and expression of CK19 mRNA in peripheral blood in NSCLC patients (P〈0.001). The detection of serum VEGF levels and CK19 mRNA in peripheral blood is helpful in judging the condition and the prognosis of NSCLC patients, and serum VEGF levels and CK19 mRNA are independent of the pathological types of lung cancer. The micrometastasis in peripheral blood of NSCLC patients is significantly associated with serum VEGF levels. 展开更多
关键词 lung neoplasm vascular endothelial growth factor (VEGF) MICROMETASTASIS cytokeratin 19
下载PDF
Antineoplastic effects of deoxyelephantopin,a sesquiterpene lactone from Elephantopusscaber, on lung adenocarcinoma (A549) cells 被引量:5
10
作者 Farha A. Kabeer Geetha B. Sreedevi +4 位作者 Mangalam S. Nair Dhanya S. Rajalekshmi LathaP. Gopalakrishnan Sujathan Kunjuraman Remani Prathapan 《Journal of Integrative Medicine》 SCIE CAS CSCD 2013年第4期269-277,共9页
OBJECTIVE: Deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, showed inhibition of the growth of various tumor cells in vitro. In the present study, we investigated the cytotoxicity and apoptosis-in... OBJECTIVE: Deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, showed inhibition of the growth of various tumor cells in vitro. In the present study, we investigated the cytotoxicity and apoptosis-inducing capacity of deoxyelephantopin on lung adenocarcinoma (A549) cells. METHODS: The cytotoxic effect of deoxyelephantopin on A549 cells and normal lymphocytes was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and 50% inhibitory concentration (IC50) value was determined. The self-renewal and proliferating potential of A549 cells after treatment with deoxyelephantopin were examined by colony formation assay. Cellular morphology of deoxyelephantopin-treated cells was observed using phase- contrast microscopy. The induction of apoptosis was evaluated using acddine orange and ethidium bromide staining, Hoechst 33342 staining, terminal deoxynucleotidyl transferase-mediated dUTP biotin nick end-labeling (TUNEL) assay, DNA fragmentation analysis and Annexin V-fluorescein isothiocyanate staining by flow cytometry. Activation of caspases was detected using fluorogenic substrate specific to caspases 2, 3, 8 and 9 and flow cytometric analysis. The total cellular DNA content and expression of cleaved poly (ADP-ribose) polymerase was also analyzed. RESULTS: Deoxyelephantopin exhibited cytotoxicity to A549 cells (IC50 = 12.287 μg/mL), however, there was no toxicity towards normal human lymphocytes. Deoxyelephantopin suppressed the colony-forming ability of A549 cells in a dose-dependent manner. Acridine orange, ethidium bromide and Hoechst 33342 staining showed cell shrinkage, chromosomal condensation and nuclear fragmentation, indicating induction of apoptosis. Deoxyelephantopin increased apoptosis of A549 cells, as evidenced by more TUNEL-positive cells. DNA fragmentation and Annexin V staining revealed late-stage apoptotic cell population. Deoxyelephantopin inhibited A549 cell growth by cell cycle arrest at G2/M phase and induced apoptosis through both extrinsic and intrinsic pathways. CONCLUSION: These results suggest that deoxyelephantopin has great potential as a new chemotherapeutic agent to be developed further for the treatment of lung cancer. 展开更多
关键词 herbal medicine lung neoplasms Elephantopus scaber deoxyelephantopin APOPTOSIS CASPASES cell line tumor A549 cells
下载PDF
阿美替尼联合贝伐珠单抗治疗晚期NSCLC伴原发EGFR T790M突变:3例病案报道及文献复习 被引量:2
11
作者 杨雪 孟凡路 钟殿胜 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第2期158-164,共7页
随着检测技术的发展,非小细胞肺癌患者(non-small cell lung cancer, NSCLC)伴原发表皮生长因子受体(epidermal growth factor receptor, EGFR)T790M突变的检出率不断增加,而针对原发EGFR T790M突变NSCLC的一线治疗尚无标准。本文中我... 随着检测技术的发展,非小细胞肺癌患者(non-small cell lung cancer, NSCLC)伴原发表皮生长因子受体(epidermal growth factor receptor, EGFR)T790M突变的检出率不断增加,而针对原发EGFR T790M突变NSCLC的一线治疗尚无标准。本文中我们报道了3例晚期NSCLC伴EGFR敏感突变及原发T790M突变的治疗经验,3例患者一线初治均为阿美替尼联合贝伐珠单抗。其中,1例在治疗3个月后因出血风险停用贝伐珠单抗并于10个月后更换为奥希替尼;1例患者在治疗13个月后更换为奥希替尼并停用贝伐珠单抗。3例患者最佳疗效均达部分缓解(partial response,PR)。随访至2022年10月,2例患者一线治疗后进展,无进展生存期(progression-free survival, PFS)分别为11个月和7个月;1例患者治疗后持续反应,治疗时间已达19个月。2例患者基线伴有多发脑转移,一线治疗后颅内病灶最佳疗效均为PR,颅内PFS分别为14个月和未达到(16+个月)。3例患者在治疗期间未见新的不良反应,未发生3级以上不良反应。此外,我们总结了NSCLC伴原发EGFR T790M突变的研究进展。总之,阿美替尼联合贝伐珠单抗初始治疗晚期NSCLC伴原发EGFR T790M突变具有较高的客观缓解率(objective response rate, ORR)及颅内病灶的控制能力,可作为晚期NSCLC伴原发EGFR T790M突变的一线治疗。 展开更多
关键词 阿美替尼 原发T790M突变 贝伐珠单抗 肺肿瘤
下载PDF
Detection of circulating tumor cells (CTCs) in patients with lung carcinoma by real-time fluorescent quantitative-PCR approach before and after chemotherapy 被引量:1
12
作者 Ming-Jian Ge Qing-Chen Wu +4 位作者 Mei Wang Li Li Xiao-Long Zhao Qiao-Min Huang Liang-Bin Li 《Health》 2009年第3期231-238,共8页
Circulating tumour cells (CTCs) are referred to the tumour cells that disseminated from the primary tumour and survive in circulating during the pro-ceeding of tumour growth. As surgical treatment evolves and local co... Circulating tumour cells (CTCs) are referred to the tumour cells that disseminated from the primary tumour and survive in circulating during the pro-ceeding of tumour growth. As surgical treatment evolves and local control has improved, the failure of cancer treatment has largely remained the re-sult of systemic metastasis. Selection of patients most likely to benefit from adjuvant strategies remains problematic. In order to develop a new standard of curative effect, this study was de-signed to track the number of CTCs in patients with lung cancer during chemotherapy. Methods: Samples of peripheral blood was taken from each lung cancer patients (n=32) on the day before chemotherapy as well as the third week after the chemotherapy cycle. The samples were subjected to real-time fluorescent quantitative reverse-tran- scriptase polymerase chain reaction (fqRT-PCR). Meanwhile the tumour size was determined by chest X-ray or computed tomograghy. Results Compared to that of pre-chemotherapy, the ex-pression level of cytokeratin (CK) 19 in the pa-tients significantly declined after chemotherapy (t=4.659,P=0.000). The level of CK19 mRNA in pa-tients with small cell lung cancer (SCLC) was higher than that of patients with non-small cell lung cancer (NSCLC) (t=1.944, P=0.061). The de-crease of CK19 mRNA level correlated well with the type during the treatment. Relatively the de-crease of SCLC is more obvious (t=6.073,P=0.000). The variation of CK19 mRNA level before and after chemotherapy was positively related to the dis-parity of tumour burden (r=0.593). There was also a significant association between the type (NSCLC vs. SCLC) and the change of tumour size (t=3.686, P=0.001).The positive rate before chemotherapy Supported by grant from the Natural Science Foundation in China (No.30972961). was 71.9% (23/32), while that after chemotherapy was 37.5% (12/32), indicating that 11 patients con- verted into negative after chemotherapy. Of the 16 patients which were in Ⅳ-stage, 11 cases were po- sitive (11/16,68.8%). Surprisingly, of the remaining 16 patients which were Ⅱ/Ⅲ stage, 12 cases were regarded as positive according to the criteria (12/6,75%). Conclusions: The real-time flu- ores-cent quantitative-PCR approach is useful for mea- suring the relative number of CTCs in a patients’ peripheral blood to monitor the effectiveness of treatment, and for designing more comprehensive and reasonable therapeutic regimes at earlier dates for patients. The treatment response can be immediately assessed by serial quantitation of CTCs after chemotherapy, and therefore this method highlights an alternative approach to rapidly access the patient’s response to treatment. 展开更多
关键词 lung neoplasm Blood POLYMERASE Chain Reaction CYTOKERATIN MESSENGER RNA CHEMOTHERAPY
下载PDF
烟草烟雾通过ROS/Sirt3/SOD2通路诱导NSCLC细胞吉非替尼耐药 被引量:1
13
作者 訾亚婉 廖科 陈虹 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第4期245-256,共12页
背景与目的表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是非小细胞肺癌(non-small cell lung cancer,NSCLC)最常见的驱动基因突变。为延长患者生存时间,NSCLC EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitors,T... 背景与目的表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是非小细胞肺癌(non-small cell lung cancer,NSCLC)最常见的驱动基因突变。为延长患者生存时间,NSCLC EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)耐药是目前急需解决的重大难题。本研究主要探究烟草烟雾(cigaree smoke,CS)诱导NSCLC发生吉非替尼耐药的机制。方法体外培养PC-9、A549细胞,分别经1μmol/L吉非替尼处理4 h、10%CS萃取物(CS extract,CSE)处理48 h。Western blot检测沉默蛋白3(Sirtuin 3,Sirt3)、超氧化物歧化酶2(superoxide dismutase 2,SOD2)蛋白表达,使用DCFH-DA探针检测细胞内活性氧(reactive oxygen species,ROS)水平,CCK-8试剂盒检测细胞活性,Ed U检测细胞增殖能力。Sirt3过表达质粒(OV-Sirt3)转染于PC-9和A549细胞中、N-乙酰半胱氨酸乙酯(N-acetylcysteine,NAC)作用于细胞后分别经1μmol/L吉非替尼处理4 h和10%CSE处理48 h。Western blot检测Sirt3、SOD2蛋白表达,DCFH-DA探针检测细胞中的ROS水平,CCK-8检测细胞活性。结果CSE均可促使PC-9、A549细胞对吉非替尼的半数抑制浓度(50%inhibitory concentration,IC_(50))提高(P<0.01),并且增强PC-9和A549细胞的增殖能力,提示CS可诱导NSCLC吉非替尼耐药;ROS参与CSE诱导的吉非替尼耐药(P<0.05);CSE诱导Sirt3、SOD2低表达(P<0.01),且Sirt3/SOD2与肺癌患者不良预后有关(P<0.05);OV-Sirt3的PC-9、A549细胞可逆转CSE诱导的吉非替尼耐药(P<0.05)且显著降低ROS生成;NAC可逆转CSE诱导的PC-9、A549细胞吉非替尼耐药(P<0.05)。结论ROS/Sirt3/SOD2通路参与了CS诱导的NSCLC吉非替尼耐药。 展开更多
关键词 肺肿瘤 烟草烟雾 ROS Sirt3/SOD2 吉非替尼耐药
下载PDF
Analysis of the Long-term Effect of Intraoperative Radiotherapy (IORT) for Non-Small Cell Lung Carcinoma (NSCLC) 被引量:2
14
作者 Guxia Zhou Tiwen Zeng Lianyuan Wang Lin Ma 《Chinese Journal of Clinical Oncology》 CSCD 2007年第1期65-70,共6页
OBJECTIVE To analyze the long-term effects of treatment with an op-eration + postoperative irradiation (A group) and an operation+intraoperative radiotherapy+postoperative irradiation (B group) in non-small cell lung ... OBJECTIVE To analyze the long-term effects of treatment with an op-eration + postoperative irradiation (A group) and an operation+intraoperative radiotherapy+postoperative irradiation (B group) in non-small cell lung cancer patients. METHODS Through a prospective randomized clinical trial, a total of 154 patients with non-small cell lung carcinoma were divided into two groups of 77 cases. Among the 154 cases, there were 134 squamous carcinomas, 17 adenocarcinomas and 3 adeno-squamous carcinomas. TNM staging: there were 17 in StageⅠ, 76 in Stage Ⅱ and 61 in Stage Ⅲ. A dosage of 15~25 Gy IORT, energy 9~16 MeV electrons, was delivered to the tumors. The doses given were 40~60 Gy postoperation. RESULTS The local control rates in A and B groups were 49.4% and 62.3% respectively (P<0.05). The survivals at 3, 5 and 7 years for group A were 40.3%, 27.3%, and 5.2% and for group B 44.2%, 28.6% and 6.5% (P>0.05). There were 16 deaths from radiotherapy complications, with 2 cases in group A and 14 in group B. CONCLUSION IORT+postoperative irradiation can enhance the local control rate of non-small cell lung cancer patients and reduce the recurrent rates, but it can not improve long-term survival. 展开更多
关键词 非小细胞肺癌 术中放射疗法 外科治疗 长期疗效 临床分析 预后
下载PDF
晚期EGFR阳性NSCLC患者PD-L1表达特点及其与EGFR-TKIs治疗疗效关系的真实世界研究 被引量:2
15
作者 陈然 高翔 +3 位作者 徐福东 张树才 马丽 胡波 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第3期217-227,共11页
背景与目的晚期表皮生长因子受体(epidermal growth factor receptor,EGFR)阳性非小细胞肺癌(nonsmall cell lung cancer,NSCLC)患者的一线治疗首选EGFR酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,... 背景与目的晚期表皮生长因子受体(epidermal growth factor receptor,EGFR)阳性非小细胞肺癌(nonsmall cell lung cancer,NSCLC)患者的一线治疗首选EGFR酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)。晚期驱动基因阴性,程序性死亡配体1(programmed cell death ligand 1,PD-L1)阳性或高表达的NSCLC患者一线治疗推荐免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)单药治疗或ICIs联合化疗。所以不同PD-L1表达水平的EGFR阳性晚期NSCLC患者的一线治疗策略值得进一步探究。既往众多研究提示PD-L1的表达明显受EGFR突变情况的影响,PD-L1表达很有可能与EGFR-TKIs耐药机制相关。本研究旨在分析晚期EGFR阳性NSCLC患者PD-L1表达特点及其与EGFR-TKIs疗效的关系。方法以159例EGFR阳性初治晚期NSCLC患者(其中包含141例EGFR敏感突变患者)为研究对象,分析159例患者相关临床病理特征与PD-L1表达的关系及141例EGFR敏感突变患者EGFR-TKIs治疗疗效的的相关影响因素。结果所纳入159例患者PD-L1表达按肿瘤细胞阳性比例分数(tumor proportion score,TPS)分类:阴性(TPS<1%)占47.2%,低表达(1%≤TPS<50%)占32.1%,高表达(TPS≥50%)占20.7%。癌细胞病理形态学分类实体为主型患者更容易出现PD-L1高表达(高表达占比52.9%,组间差异P<0.0001)。PD-L1阴性表达、低表达、高表达患者一线接受一代EGFR-TKIs治疗的中位无进展生存期分别为12.4个月、10.5个月和3.7个月,三者间差异有明显统计学意义(P<0.0001);EGFR-TKIs治疗期间,有肺部病灶放疗史相对于无肺部病灶放疗史有更长的无进展生存期获益(中位无进展生存期:17.0个月vs 9.3个月,P<0.0001)。结论晚期EGFR阳性NSCLC患者PD-L1的表达水平与癌细胞病理形态学分类显著相关。PD-L1高表达NSCLC患者接受EGFR-TKIs疗效明显较差。靶向治疗期间联合肺部病灶放疗可以显著延长无进展生存期。 展开更多
关键词 肺肿瘤 EGFR突变 PD-L1表达 靶向治疗
下载PDF
SWI/SNF复合体基因突变促进NSCLC细胞在NSI小鼠体内肝转移的研究
16
作者 高玲玲 谢至 +14 位作者 林首恒 吕志异 周文斌 陈冀 朱琳琳 张莉 曾鹏辉 黄晓丹 颜文青 陈宇 卢丹霞 张水莲 郭伟浜 李鹏 张绪超 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第10期753-764,共12页
背景与目的SWI/SNF复合体(switch/sucrose nonfermentable chromatin-remodeling complex,SWI/SNF)是一种重要的染色质重塑复合物,其亚基变异在多种肿瘤中存在,并与多种肿瘤细胞生物学特征相关。但其基因突变是否参与非小细胞肺癌(non-s... 背景与目的SWI/SNF复合体(switch/sucrose nonfermentable chromatin-remodeling complex,SWI/SNF)是一种重要的染色质重塑复合物,其亚基变异在多种肿瘤中存在,并与多种肿瘤细胞生物学特征相关。但其基因突变是否参与非小细胞肺癌(non-small cell lung cancer,NSCLC)肝转移过程尚不清楚。本研究拟探究SWI/SNF复合体基因突变对NSCLC肝转移的影响及潜在机制。方法我们使用全外显子组测序(whole-exome sequencing,WES)分析了NSCLC细胞H1299、H23和H460中SWI/SNF复合体基因突变。通过CRISPR/Cas9(clustered regularly interspaced short palindromic repeats)技术构建了ARID1A基因稳定敲除的H1299细胞株,建立了小鼠模型模拟NSCLC肝转移,观察不同基因突变对肝转移的影响。利用RNA-Seq和蛋白印迹分析差异基因的表达,并通过免疫组化技术(immunohistochemistry,IHC)检测了SWI/SNF复合体调控的靶分子在小鼠肝转移灶中的表达。结果WES分析确定了SWI/SNF复合体基因的突变情况。动物实验结果显示SWI/SNF复合体基因突变与免疫缺陷小鼠较高的肝转移率相关。转录组测序和蛋白印迹分析显示SWI/SNF复合体基因突变细胞中ALDH1A1和APOBEC3B表达上调,尤其是ARID1A蛋白缺失的H460和H1299 sgARID1A中ALDH1A1表达水平显著上升。IHC染色亦显示H460和H1299 sgARID1A细胞肝转移灶中ALDH1A1高表达。结论本研究强调了SWI/SNF复合体基因ARID1A和SMARCA4等突变在促进肺癌细胞肝转移中的关键作用。这些基因突变可能通过促进ALDH1A1与APOBEC3B高表达进而发挥肝特异性转移的作用,为深入探究肺癌肝转移分子机制提供了新线索。 展开更多
关键词 肺肿瘤 SWI/SNF复合体 突变 肿瘤转移
下载PDF
The value of chest CT scan and tumor markers detection in sputum for early diagnosis of peripheral lung cancer 被引量:2
17
作者 WANGXu CAOAihong PENGMengqing HUChunfeng LIUDelin GUTao LIUHui 《中国肺癌杂志》 CAS 2004年第1期58-63,共6页
Objective To investigate the diagnostic value of chest CT scan combined with telomerase activity and p16 gene methylation from exfoliated cells of sputum in 55 cases of solitary pulmonary nodules (SPN; ≤30 mm)suspect... Objective To investigate the diagnostic value of chest CT scan combined with telomerase activity and p16 gene methylation from exfoliated cells of sputum in 55 cases of solitary pulmonary nodules (SPN; ≤30 mm)suspected early peripheral lung cancer. Methods The sputum specimens from 34 cases of cancer nodules and 21 cases of benign lesion were detected for telomerase activity by TRAP PCR ELISA and p16 gene methylation by PCR based methylation analysis. Results The qualitative diagnostic accuracy of CT scan was 61.8%(34/55) for SPN provided by pathology. Cytology analysis of sputum was positive in 13 cases (38.2%). Telomerase activity was positive in 29 cases: sensitivity was 79.4%, specificity was 90.5%, accuracy was 83.6%; p16 gene methylation was found in 11 cases: sensitivity was 32.4%, specificity was 100.0% , and accuracy was 58.2%. The sensitivity was increased to 86.1% by combination of telomerase activity and p16 gene methylation. Compared with nodules without malignant CT signs, expression of telomerase activity and p16 methylation of SPN with malignant CT signs (lobulation or spiculate protuberance or spicule sign) had a significant difference ( P <0.01). Conclusion The results suggest that chest CT scan combined with telomerase activity and p16 gene methylation detection in sputum for patients with peripheral lung cancer may enhance the diagnostic value of radiology and conventional cytology. 展开更多
关键词 胸部CT扫描 诊断 肿瘤标记物 早期 周围型肺癌
下载PDF
EGFR外显子20插入突变型NSCLC治疗的研究进展 被引量:3
18
作者 徐美怡 罗佳伟 许瑞莲 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第2期151-157,共7页
肺癌已成为对人类健康威胁最大的肿瘤之一,死亡率位居肿瘤死因之首,非小细胞肺癌(non-small cell lung cancer, NSCLC)占肺癌的80%-85%,晚期NSCLC的治疗以化疗为主,但5年的生存率较低。表皮生长因子受体(epidermal growth factor recept... 肺癌已成为对人类健康威胁最大的肿瘤之一,死亡率位居肿瘤死因之首,非小细胞肺癌(non-small cell lung cancer, NSCLC)占肺癌的80%-85%,晚期NSCLC的治疗以化疗为主,但5年的生存率较低。表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变是肺癌中最常见的驱动基因变异,而EGFR外显子20插入(EGFR exon 20 insertions,EGFRex20ins)突变型属于其中一种罕见突变,在所有EGFR突变中占4%-10%,在NSCLC中约占1.8%。近年来,以EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors, EGFR-TKIs)为代表的靶向治疗已经成为晚期NSCLC患者一个重要的治疗选择,然而EGFR ex20ins突变型的NSCLC患者对大部分EGFR-TKIs治疗并不敏感。目前,部分针对EGFR ex20ins突变的靶向药物取得了明显疗效,部分药物仍在临床研究中。本文将针对EGFR ex20ins突变的各种治疗方法及其疗效进行阐述。 展开更多
关键词 肺肿瘤 EGFR外显子20插入突变 EGFR突变 靶向治疗
下载PDF
MET 14外显子跳跃突变NSCLC靶向治疗专家共识
19
作者 中国老年保健协会肺癌专业委员会 陈军 +9 位作者 李昕 刘夏 刘东颖 孟庆威 邬麟 徐嵩 徐燕 张琳琳 张新伟 赵洪林 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第6期416-428,共13页
间质-上皮细胞转化因子(mesenchymal-epithelial transition factor,MET)14外显子跳跃突变主要由于c-Cbl酪氨酸结合位点丢失导致,从而引起蛋白酶体介导的MET蛋白降解率降低,引发下游通路的持续激活,最终导致肿瘤发生。非小细胞肺癌(non-... 间质-上皮细胞转化因子(mesenchymal-epithelial transition factor,MET)14外显子跳跃突变主要由于c-Cbl酪氨酸结合位点丢失导致,从而引起蛋白酶体介导的MET蛋白降解率降低,引发下游通路的持续激活,最终导致肿瘤发生。非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中MET 14外显子跳跃突变的发生率为0.9%-4.0%,晚期NSCLC患者应进行MET14外显子跳跃突变的检测,以筛选MET抑制剂靶向治疗获益人群。MET抑制剂客观缓解率均较高,安全性良好,为MET 14外显子跳跃突变NSCLC患者带来新希望。中国老年保健协会肺癌专业委员会组织专家结合临床实践经验及循证医学证据,针对MET 14外显子跳跃突变NSCLC靶向治疗的临床问题给予专家建议,制定《MET 14外显子跳跃突变NSCLC靶向治疗专家共识》,旨在为中国医师的临床实践提供规范化指导。 展开更多
关键词 肺肿瘤 MET 14外显子跳跃突变 MET抑制剂 靶向治疗
下载PDF
ALK抑制剂在治疗NSCLC脑转移中的疗效及安全性研究进展 被引量:1
20
作者 陈雨晨 韩寒 +2 位作者 魏晋攀 杜倩宇 王西勇 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第5期400-406,共7页
肺癌是全球死亡率最高的恶性肿瘤之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占所有肺癌病理类型的80%-85%。NSCLC中有30%-55%的患者发生脑转移。据估计,5%-6%的脑转移患者存在间变性淋巴瘤激酶(anaplastic lymphoma kina... 肺癌是全球死亡率最高的恶性肿瘤之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占所有肺癌病理类型的80%-85%。NSCLC中有30%-55%的患者发生脑转移。据估计,5%-6%的脑转移患者存在间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合。ALK融合阳性NSCLC患者在接受ALK抑制剂后获得了非常显著的疗效。经过十余年的迅速发展,ALK抑制剂已经形成三代同堂的局面:即第一代——克唑替尼(Crizotinib);第二代——阿来替尼(Alectinib)、布格替尼(Brigatinib)、塞瑞替尼(Ceritinib)、恩沙替尼(Ensartinib);第三代——洛拉替尼(Lorlatinib)。这些药物在ALK融合阳性NSCLC脑转移患者中显示出不同的疗效。由于此类药物众多,ALK抑制剂的选择给临床医生带来了困扰。因此,本文旨在对ALK抑制剂在NSCLC脑转移中的治疗效果和安全性进行综述,以期为临床医生提供治疗选择的依据。 展开更多
关键词 肺肿瘤 ALK抑制剂 脑转移 疗效 安全性
下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部